Review
doi: 10.1016/j.ctrv.2021.102179.
Epub 2021 Mar 19.
Immunotherapy in non-small cell lung cancer harbouring driver mutations
Affiliations
- PMID: 33798954
- DOI: 10.1016/j.ctrv.2021.102179
Item in Clipboard
Review
Immunotherapy in non-small cell lung cancer harbouring driver mutations
Cancer Treat Rev.
2021 May.
Free article
No abstract available
Similar articles
-
Therapeutic Implications of Tumor Microenvironment in Lung Cancer: Focus on Immune Checkpoint Blockade.Front Immunol. 2022 Jan 7;12:799455. doi: 10.3389/fimmu.2021.799455. eCollection 2021. Front Immunol. 2022. PMID: 35069581 Free PMC article. Review.
-
NLRP4 negatively regulates type I interferon response and influences the outcome in anti-programmed cell death protein (PD)-1/PD-ligand 1 therapy.Cancer Sci. 2022 Mar;113(3):838-851. doi: 10.1111/cas.15243. Epub 2022 Jan 19. Cancer Sci. 2022. PMID: 34927309 Free PMC article.
-
Cancer immunotherapy resistance based on immune checkpoints inhibitors: Targets, biomarkers, and remedies.Drug Resist Updat. 2020 Dec;53:100718. doi: 10.1016/j.drup.2020.100718. Epub 2020 Jul 15. Drug Resist Updat. 2020. PMID: 32736034 Review.
-
CD103+CD8+ TRM Cells Accumulate in Tumors of Anti-PD-1-Responder Lung Cancer Patients and Are Tumor-Reactive Lymphocytes Enriched with Tc17.Cell Rep Med. 2020 Oct 20;1(7):100127. doi: 10.1016/j.xcrm.2020.100127. eCollection 2020 Oct 20. Cell Rep Med. 2020. PMID: 33205076 Free PMC article.
-
Tumor immune microenvironment of EGFR-mutant non-small-cell lung cancer and its impact on therapeutic efficacy.Immunotherapy. 2020 May;12(7):431-437. doi: 10.2217/imt-2019-0213. Epub 2020 Apr 22. Immunotherapy. 2020. PMID: 32316809 No abstract available.
Cited by
-
Response of an HER2-Mutated NSCLC Patient to Trastuzumab Deruxtecan and Monitoring of Plasma ctDNA Levels by Liquid Biopsy.Curr Oncol. 2023 Jan 30;30(2):1692-1698. doi: 10.3390/curroncol30020130. Curr Oncol. 2023. PMID: 36826091 Free PMC article.
-
Multicellular Effects of STAT3 in Non-small Cell Lung Cancer: Mechanistic Insights and Therapeutic Opportunities.Cancers (Basel). 2021 Dec 11;13(24):6228. doi: 10.3390/cancers13246228. Cancers (Basel). 2021. PMID: 34944848 Free PMC article. Review.
-
Novel RAF-directed approaches to overcome current clinical limits and block the RAS/RAF node.Mol Oncol. 2024 Jun;18(6):1355-1377. doi: 10.1002/1878-0261.13605. Epub 2024 Feb 16. Mol Oncol. 2024. PMID: 38362705 Free PMC article. Review.
-
Calls to action on lung cancer management and research.Oncologist. 2024 Dec 6;29(12):e1634-e1645. doi: 10.1093/oncolo/oyae169. Oncologist. 2024. PMID: 39002167 Free PMC article.
-
Genomic Characterization of Concurrent Alterations in Non-Small Cell Lung Cancer (NSCLC) Harboring Actionable Mutations.Cancers (Basel). 2021 Apr 30;13(9):2172. doi: 10.3390/cancers13092172. Cancers (Basel). 2021. PMID: 33946519 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials
